Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
USE OF ADAM9 INHIBITOR AS IMMUNOMODULATOR
Document Type and Number:
WIPO Patent Application WO/2020/216319
Kind Code:
A1
Abstract:
A use of an ADAM9 inhibitor in preparing an immunomodulator. The immunomodulator can change the distribution of immune cells in a tumor and increase the infiltration of the immune cells, thereby increasing the efficacy of cancer immunotherapy.

Inventors:
SHER YUH-PYNG (CN)
YANG JUAN-CHENG (CN)
LIU JING-PEI (CN)
HUANG YU-KAI (CN)
Application Number:
PCT/CN2020/086642
Publication Date:
October 29, 2020
Filing Date:
April 24, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV CHINA MEDICAL (CN)
International Classes:
A61K31/427; A61P35/00; A61P37/02
Domestic Patent References:
WO2004024089A22004-03-25
WO2007044515A12007-04-19
Foreign References:
TW201917127A2019-05-01
CN109563152A2019-04-02
Other References:
PO-LIN KUO ET AL.: "Lung Cancer-derived Galectin-1 Enhances Tumorigenic Potentiation of Tumor-Associated Dendritic Cells by Expressing Heparin-Binding EGF-Like Growth Factor", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 13, 30 January 2012 (2012-01-30), XP055746976, ISSN: 0021-9258, DOI: 10.1074/jbc.M111.321190
SOOYEON OH ET AL.: "A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker during Hepatocellular Carcinoma Immunotherapy", CANCERS, vol. 12, no. 3, 21 March 2020 (2020-03-21), XP055746979, ISSN: 2070-6694, DOI: 10.3390/cancers12030745
See also references of EP 3960171A4
Attorney, Agent or Firm:
LECOME INTELLECTUAL PROPERTY AGENT LTD. (CN)
Download PDF: